The effect of adjuvant systemic therapy on prognostic impact of polymorphisms

<p><b>Copyright information:</b></p><p>Taken from "Association of codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients"</p><p>http://breast-cancer-research.com/content/9/3/R34</p><p>Breast Cancer Research 2007;9(3):R34-R34.</p><p>Published online 30 May 2007</p><p>PMCID:PMC1929098.</p><p></p> codon 72 and adjuvant chemotherapy alone (= 137); codon 72 and adjuvant chemotherapy with or without hormonal therapy (= 281); codon 72 and adjuvant hormonal therapy alone (= 195); codon 72 and no adjuvant systemic therapy (= 77); SNP309 and adjuvant tamoxifen with or without luteinizing hormone-releasing hormone analog (= 185). DFS, disease-free survival

Representative immunohistochemical staining of estrogen receptor (ER)-α Ser118, and ER-α Ser167 in normal breast epithelium and invasive ductal carcinoma

<p><b>Copyright information:</b></p><p>Taken from "Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer"</p><p>Breast Cancer Research 2005;7(5):R753-R764.</p><p>Published online 27 Jul 2005</p><p>PMCID:PMC1242143.</p><p>Copyright © 2005 Yamashita et al.; licensee BioMed Central Ltd.</p> Phosphorylation of ER-α Ser118 in normal breast epithelium and invasive ductal carcinoma: negative (b) and positive (c) nuclear staining was observed in carcinoma cells. Phosphorylation of ER-α Ser167 in normal breast epithelium and invasive ductal carcinoma: negative (e) and positive (f) nuclear staining was observed in carcinoma cells (magnification, 400×)

Immunoblot analysis of phosphorylated estrogen receptor (ER)-α Ser118 and ER-α Ser167

<p><b>Copyright information:</b></p><p>Taken from "Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer"</p><p>Breast Cancer Research 2005;7(5):R753-R764.</p><p>Published online 27 Jul 2005</p><p>PMCID:PMC1242143.</p><p>Copyright © 2005 Yamashita et al.; licensee BioMed Central Ltd.</p> Transfected COS-7 cells were grown in serum- and estrogen-deprived conditions and treated with vehicle (medium) (lane 1), 17β-estradiol (E) (lane 2), epidermal growth factor (EGF) (lane 3), or Eand EGF (lane 4) for 30 min. Equal amounts of total protein from whole cell lysates were blotted for either anti-ER-α-phosphoserine (α-pS118 and α-pS167) and anti-ER-α (α-ER-α) antibodies. T47D cells were grown in serum- and estrogen-deprived conditions and treated with vehicle (medium) (lane 1), 17β-estradiol (E) for 10 min (lane 2) and 30 min (lane 3), EGF for 10 min (lane 4) and 30 min (lane 5), or Eand EGF for 10 min (lane 6) and 30 min (lane 7). Equal amounts of total protein from whole cell lysates were blotted for either anti-ER-α-phosphoserine (α-pS118 and α-pS167) and anti-ER-α (α-ER-α) antibodies